Latest Safety News

Iluka Resources reported a 32% drop in net profit after tax to $231 million for 2024, while securing critical funding for its Eneabba rare earths refinery and progressing the Balranald mine development.

Nyrada Inc. posted a significant $2.46 million loss for H1 FY25, driven by increased R&D spend, while advancing its lead drug NYR-BI03 into first-in-human trials following regulatory approval.

Select Harvests Limited reported a strong financial turnaround in FY2024 with a $46 million EBITDA and a modest net profit, while facing shareholder concerns over a recent capital raise and remuneration report at its AGM.

SG Fleet Group reported a solid $41.1 million NPAT for the first half of 2025, driven by strong disposal volumes and fleet growth across Australia, New Zealand, and the UK. While profit dipped from last year, the company anticipates normalization in the second half.

MLG Oz Limited has secured a significant $75 million haulage contract with Westgold Resources, poised to generate over $25 million annually and deepen its footprint in Western Australia's Goldfields region.

Opthea has completed the final patient visit in its pivotal COAST Phase 3 trial evaluating sozinibercept combined with aflibercept for wet AMD, with topline results expected early Q2 2025.

Monadelphous Group Ltd reported a robust first half of FY2025 with revenue climbing 4.2% to $1.051 billion and net profit after tax surging 41.3%, underpinned by a strong contract pipeline and operational improvements.

Monadelphous delivered a robust first half in 2025, posting a 4.2% revenue increase to $1.051 billion and a 41.3% jump in net profit after tax, underpinned by strong contract wins and operational momentum.

Icetana Limited has successfully closed its renounceable pro rata entitlement offer, raising $629,422 through new share issuance, with convertible notes poised to convert into shares shortly.

Variscan Mines reports strong progress in its maiden underground drilling at the Udias Mine, with assay results expected soon, while advancing critical studies for a mine restart at its Novales-Udias Project.

PYC Therapeutics has launched a A$145.8 million pro-rata accelerated non-renounceable entitlement offer to fund late-stage clinical trials across its pipeline targeting rare diseases with high unmet needs. The capital raise aims to extend the company’s cash runway beyond FY27, supporting four drug candidates through critical human safety and efficacy milestones.

HyTerra Limited faces operational delays at its Nemaha Project due to severe winter weather but strengthens its management team with a key executive hire to drive 2025 exploration forward.